Aug 14 (Reuters) - Immutep Ltd (IMM) :
- IMMUTEP ANNOUNCES FIRST PARTICIPANT DOSED IN PHASE I STUDY OF IMP761, A FIRST IN CLASS AGONIST LAG-3 ANTIBODY
- SAFETY DATA FROM FIRST-IN-HUMAN STUDY ANTICIPATED BY YEAR-END AND PHARMACOKINETICS AND PHARMACODYNAMICS DATA IN FIRST HALF CY2025
News: IMM Immutep Announces First Participant Dosed In Phase I Study Of Imp761
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.3¢ |
Change
0.003(1.09%) |
Mkt cap ! $337.6M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.0¢ | 23.0¢ | $38.35K | 164.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 440049 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 277050 | 23 |
View Market Depth
| Last trade - 10.31am 10/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |